French drugmaker Sanofi is in advanced talks to buy Actelion Ltd and is discussing a price of about $275 per share for the Swiss drugmaker, Bloomberg reported on Thursday.
The potential deal, which could come as soon as next week, would value Actelion at about $29.6 billion, Bloomberg reported, citing people with knowledge of the matter, reports Reuters.
Actelion is in talks with Sanofi about a deal, Reuters reported on Wednesday, after U.S. healthcare group Johnson & Johnson abandoned efforts to buy the company. Sanofi and Actelion could not immediately be reached for comment.
